Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05092_nanopub.RA_xkbSQITpjwWZKsJWdzA7Z4Vukrts69-OcbX-qCOuE0#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- drugbank:DB05092 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05092 label "CDP323 [drugbank:DB05092]" assertion.
- drugbank:DB05092 seeAlso DB05092 assertion.
- drugbank:DB05092 description "CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis." assertion.
- drugbank:DB05092 identifier "drugbank:DB05092" assertion.
- drugbank:DB05092 title "CDP323" assertion.
- drugbank:DB05092 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05092 drugbank_vocabulary:drugbank-id "DB05092" assertion.
- drugbank:DB05092 bio2rdf_vocabulary:x-identifiers.org DB05092 assertion.
- drugbank:DB05092 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05092" assertion.
- drugbank:DB05092 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05092 bio2rdf_vocabulary:identifier "DB05092" assertion.
- drugbank:DB05092 drugbank_vocabulary:x-wikipedia wikipedia:CDP323 assertion.